ESLA Q1 2025 Earnings — Estrella Immunopharma, Inc. Revenue & Financial Results | Market Cap Arena

ESLAEstrella Immunopharma, Inc.

$53M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$2M

Net Income

-$2M

EPS (Diluted)

$-0.06

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$465,981

Free Cash Flow

-$465,981

Stock-Based Comp.

$159,095

Balance Sheet

Total Assets

$2M

Total Liabilities

$4M

Stockholders' Equity

-$2M

Cash & Equivalents

$421,473

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$2M	-$469,530	-348.2%
Net Income	-$2M	-$469,530	-348.2%